Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has provided an announcement.
Shanghai Fosun Pharmaceutical has announced the composition of its board of directors, which includes 12 members with roles spanning executive, non-executive, and independent non-executive positions. The announcement details the membership of board committees, which are integral to the company’s strategic, audit, nomination, remuneration, and environmental governance functions, indicating a structured approach to corporate governance.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development, manufacturing, and distribution of pharmaceutical products and healthcare services.
YTD Price Performance: 10.51%
Average Trading Volume: 5,648
Technical Sentiment Signal: Sell
Current Market Cap: $8B
See more insights into 2196 stock on TipRanks’ Stock Analysis page.